ACROBiosystems

Recombinant Human TGF-Beta 2 Protein

Cat. # TG2-H4213 For Research and Further Cell Culture Manufacturing Use

Source: Bioactivity: Recombinant Human TGF Beta 2 Protein (rhTGFB2) The bio-activity was determined by its ability to Ala 303 - Ser 414 (Accession # NP_003229.1) was inhibit IL-4 induced HT-2 cell proliferation. ED50<0.1 produced in human HEK293 cells at ACRObiosystems. ng/ml, corresponding to a specific activity of >1X107 Unit/mg Molecular Characterization: Formulation: rhTGFB2 contains no “tags” and has a calculated MW of 12.7 kDa (monomer). DTT-reduced protein migrates Lyophilized from 0.22 μm filtered solution in TFA, as a 13 kDa polypeptide and the non-reduced cystine- acetonitrile. Normally Mannitol or Trehalose are linked homodimer migrates as a 25 kDa protein. added as protectants before lyophilization. Contact us for customized product format or Endotoxin: formulation. Less than 1.0 EU per μg of the rhTGFB2 by the LAL Reconstitution : method. See Certificate of Analysis for details of Purity: reconstitution instruction and specific concentration. >98% as determined by SDS-PAGE of reduced (+) and Storage: non-reduced (-) rhTGFB2. Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: SDS-PAGE: • 4-8℃ for 1 year in lyophilized state The purity of rhTGFB2 • 4-8℃ for 1 month under sterile conditions after was determined by SDS- reconstitution PAGE of reduced (+) and • -20 ℃ to -70 ℃ for 3 months under sterile non-reduced (-) rhTGFB2 conditions after reconstitution and staining overnight with Coomassie Blue.

Background: Transforming beta 2 ( TGFB2) is also known as TGF-β2, TGF-beta2, Glioblastoma-derived T-cell suppressor factor, G-TSF, BSC-1 cell growth inhibitor, Polyergin, Cetermin, and is a polypeptide member of the transforming growth factor beta superfamily of . It is a secreted protein known as a that performs many cellular functions and has a vital role during embryonic development. Mature human TGF-β2 shows 100% aa identity with porcine, canine, equine and bovine TGF-β2, and 97% aa identity with mouse and rat TGF-β2. It demonstrates crossspecies activity [1]. It is an extracellular glycosylated protein. It is known to suppress the effects of dependent T-cell tumors. The increased levels of TGF beta 2 triggered a neuronal cell death pathway related to Alzheimer's disease (AD) by binding to the extracellular domain of amyloid beta precursor protein (APP). The upregulation of the TGF beta 2 level is a common pathological feature of AD brains and suggests that it may be closely linked to the development of neuronal death related to AD. TGF-beta regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. TGF beta 2 suppression is a promising therapeutic approach for malignant tumor therapy.[2-3] Please contact us via [email protected], if you have any question on this product. References: (1) Sporn, M.B., 2006, Cytokine Growth Factor Rev. 17:3-7. (2) Noguchi A. et al., 2010, Int J Neurosci. 120(3): 168-75. (3) Schlingensiepen KH. et al., 2006, Cytokine Growth Factor Rev. 17(1-2): 129-39.

http://www.acrobiosystems.com